Pediatric Medicines Market Key Highlights:
- Market Size (2024): USD 111.34 Billion
- Projected Market Size (2034): USD 168.01 Billion
- CAGR (2023-2034): 4.2%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Pediatric Medicines Market
The pediatric medicines market deals in the manufacturing and distribution of childcare medicines across the world. The main types of pediatric medicines that are available in the market consist of cancer therapies, allergy and respiratory drugs, anti-infectives, hormone drugs, urological drugs, and some others. These medicines are administered using various routes, including oral, topical, parental, and some others. The rising emphasis on child treatment, along with increased investment in the healthcare sector, has shaped the industry in a positive direction. This market is likely to rise significantly with the growth of the healthcare industry across the world.
The rising prevalence of chronic diseases among children, along with an increase in research and development activities for manufacturing pediatric therapies, has boosted the market growth. Also, the availability of these drugs in hospital pharmacies, retail pharmacies, online pharmacies, and other places is contributing significantly to the industrial expansion. Moreover, the increasing number of hospitals, specialty clinics, homes, and others related to pediatrics has propelled the growth of the pediatric medicines market.
Advancements in the medical devices industry along with growing emphasis on vaccine manufacturing and universal screening technologies are expected to create ample growth opportunities for the market players in the future. In April 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) had approved Lutathera. Lutathera is a medicine used in the treatment of somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors in children above 12 years of age.
Pediatric Medicines Market Segmentation:
By Type
- Enteral
- Parenteral
- Topical
By Application
Pediatric Medicines Market Companies:
- GSK
- Novartis
- Pfizer
- Sanofi
- Abbott
- Bristol-Myers Squibb
- Cipla
- Eisai Pharmaceuticals
- Eli Lilly
- F. Hoffman-La Roche
- Glenmark
- Helsinn Healthcare
- Heron Therapeutics
- Ipca Laboratories.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
